Meeting
2018 ASCO Annual Meeting
Safety and efficacy results from a phase I dose-escalation trial of Nintedanib in combination with Pembrolizumab in patients with advanced solid tumors (PEMBIB trial).
Authors
Andreea Varga
Gustave Roussy Cancer Campus, Villejuif, France
Andreea Varga , Capucine Baldini , Patricia Martin-Romano , Benjamin Besse , David Planchard , Stephane Champiat , ERIC ANGEVIN , Antoine Hollebecque , Rastislav Bahleda , Anas Gazzah , Jean-Pierre Armand , Xavier Paoletti , Christophe Massard , Jean-Charles Soria , Aurelien Marabelle
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics—Immunotherapy
Track
Developmental Therapeutics and Translational Research
Sub Track
Immune Checkpoint Inhibitors
Clinical Trial Registration Number
NCT02856425
Citation
J Clin Oncol 36, 2018 (suppl; abstr 3080)
DOI
10.1200/JCO.2018.36.15_suppl.3080
Abstract #
3080
Poster Bd #
294
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
Phase 1 study of OBT076, a first-in-class anti-DEC205 ADC, in patients with advanced/metastatic solid tumors: Safety, efficacy, and PK/PD results.
First Author: Olivier Rixe
Poster
2021 ASCO Annual Meeting
Safety and efficacy of AK112, an anti-PD-1/VEGF-A bispecific antibody, in patients with advanced solid tumors in a phase I dose escalation study.
First Author: Jermaine Coward
Poster
2024 ASCO Breakthrough
Efficacy and safety of surufatinib plus toripalimab in previously treated advanced tumors progressing after immunotherapy.
First Author: Panpan Zhang
Poster
2023 ASCO Annual Meeting
A phase 1 dose-escalation study to investigate the safety, efficacy, pharmacokinetics, and pharmacodynamic activity of cln-619 (Anti-MICA/B antibody) alone and in combination with pembrolizumab in patients with advanced solid tumors.
First Author: Judy S. Wang